

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Fukumura *et al.*

Appl. No: 09/720,979 (U.S. National Stage of  
PCT/JP99/03552)

International Filing Date: July 1, 1999

For: **Negative-Sense RNA Virus Vector for  
Nerve Cell**

Art Unit: 1636

Examiner: to be assigned

Atty. Docket: 4001-0003

**STATEMENT TO SUPPORT FILING AND SUBMISSION OF SUBSTITUTE  
SEQUENCE LISTING IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box SEQUENCE

Sir:

In connection with a substitute Sequence Listing submitted concurrently herewith,  
the undersigned hereby states that:

1. the substitute submission filed herewith in accordance with 37 C.F.R. §§ 1.821(g) and 1.825(a), does not include new matter, it simply clarifies the definitions of SEQ ID NOS: 1-3. Support for the substitute submission is found in, for example, Figure 1;
2. the content of the attached paper copy and the attached computer readable copy of the substitute Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same as required by 37 C.F.R. § 1.821(f); and
3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these

Appl. No: 09/720,979  
(U.S. National Stage of PCT/JP99/03552)  
Atty. Dkt. No: 4001-0003

statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

SHANKS & HERBERT

By: Mark R. Shanks  
Mark R. Shanks  
Reg. No. 33,781

Date: 4/14/02

TransPotomac Plaza  
1033 N. Fairfax Street  
Suite 306  
Alexandria, VA 22314  
(703) 683-3600